


CORRECTION

Open Access



Correction to: Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

Enrique Guilherme¹ , Matthias Jacquet-Lagrange^{1,2*}, Matteo Pozzi³, Felix Achana⁴, Xavier Armoiry^{5,6} and Jean-Luc Fellahi^{1,2}

Correction to: *Crit Care* 24, 442 (2020)
<https://doi.org/10.1186/s13054-020-03122-y>

Following publication of the original article [1], the authors reported errors in Table 1 and Table 2.

The revised Table 1 and Table 2 are indicated hereafter.

The original article [1] has been updated.

Author details

¹Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Anesthésie-Réanimation, Lyon, France. ²INSERM U1060, Laboratoire CarMeN, IHU OPeRa, Lyon, France. ³Hospices Civils de Lyon, Hôpital Louis Pradel, Service de Chirurgie Cardiaque, Lyon, France. ⁴Nuffield Department of Primary care, Oxford University, Oxford, UK. ⁵Lyon School of Pharmacy (ISPB), Public Health department/UMR CNRS 5510 MATEIS, I2B Team, Lyon, France. ⁶Division of Health Sciences, Warwick Medical School, Warwick university, Coventry, UK.

Published online: 05 August 2020

Reference

1. Guilherme E, Jacquet-Lagrange M, Pozzi M, et al. Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis. *Crit Care*. 2020;24:442 <https://doi.org/10.1186/s13054-020-03122-y>.

The original article can be found online at <https://doi.org/10.1186/s13054-020-03122-y>.

* Correspondence: matthias.jacquet-lagrange@chu-lyon.fr

¹Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Anesthésie-Réanimation, Lyon, France

²INSERM U1060, Laboratoire CarMeN, IHU OPeRa, Lyon, France

Full list of author information is available at the end of the article



© The Author(s). 2020, corrected publication 2020. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Patients demographic and clinical characteristics

	All (n = 200)	Levosimendan (n = 53)	Control (n = 147)	p value
Clinical characteristics at ICU admission				
Age (years)	53 ± 13.5	53.9 ± 14.3	52.6 ± 13.3	0.575
Male	129 (64.5)	33 (62.3)	96 (65.3)	0.692
BMI (kg/m ²)	25.3 ± 5.4	25.3 ± 5.6	25.3 ± 5.3	0.975
SAPS-II	52.2 ± 14.3	53.5 ± 10.8	51.7 ± 15.4	0.349
SOFA	11.7 ± 2.1	11.5 ± 1.5	11.8 ± 2.2	0.459
Comorbidities				
Hypertension	62 (31)	18 (34)	44 (29.9)	0.587
Diabetes	36 (18)	11 (20.8)	25 (17)	0.430
History of congestive heart failure	101 (51)	26 (50)	75 (51.4)	0.865
Coronary artery disease	88 (44)	27 (50.9)	61 (41.5)	0.235
Peripheral artery disease	11 (5.5)	4 (7.5)	7 (4.8)	0.446
History of stroke	14 (7)	5 (9.4)	9 (6.1)	0.418
Smoking	71 (35.5)	18 (34)	53 (36.1)	0.785
Dyslipidemia	49 (24.5)	14 (26.4)	35 (23.8)	0.705
Renal failure with dialysis	15 (7.5)	3 (5.6)	12 (8.1)	0.553
Indication for VA-ECMO				0.068
Post-cardiotomy	59 (29.5)	18 (34)	41 (27.9)	
Acute myocardial infarction	45 (22.5)	17 (32.1)	28 (19)	
Graft dysfunction	33 (16.5)	3 (5.7)	30 (20.4)	
Dilated cardiomyopathy	15 (7.5)	5 (9.4)	10 (6.8)	
Intoxication	14 (7)	0 (0)	14 (9)	
Fulminant myocarditis	13 (6.5)	3 (5.7)	10 (6.8)	
Pulmonary embolism	6 (3)	2 (3.8)	4 (2.7)	
Septic cardiomyopathy	6 (3)	2 (3.8)	4 (2.7)	
Others	9 (4.5)	3 (5.6)	6 (4)	
Potential for myocardial recovery				0.264
High	39 (19.5)	7 (13.2)	32 (21.8)	
Intermediate	86 (43)	22 (41.5)	64 (43.5)	
Low	75 (37.5)	24 (45.3)	51 (34.7)	
Hemodynamic parameters at admission				
LVEF (%)	19.6 ± 11.3	18 ± 11.1	20.2 ± 11.4	0.241
TAPSE < 12 (mm)	45 (30.8)	15 (34.8)	30 (29.1)	0.489
MAP (mmHg)	69 ± 11	70 ± 11	69 ± 11	0.643
HR (beats/min)	103 ± 24	108 ± 21	102 ± 25	0.145
CVP (mmHg)	10.6 ± 5	10.8 ± 5.5	10.6 ± 4.9	0.798
ScvO ₂ (%)	62 ± 11	60 ± 12	63 ± 11	0.065
VA-ECMO characteristics				
VA-ECMO duration (days)	7.6 ± 5	10.6 ± 4.8	6.5 ± 4.7	< 0.001
Flow rate (L/min)	3.5 ± 0.8	3.4 ± 0.8	3.5 ± 0.8	0.835
Rotation (round/min)	4360 ± 1711	4480 ± 1724	4312 ± 1710	0.547
FiO ₂ (%)	59 ± 12	58 ± 12	59 ± 13	0.977
Peripheral VA-ECMO cannulation	175 (87.5)	48 (90.6)	127 (86.4)	0.496
IABP associated to VA-ECMO	54 (27)	16 (30.1)	38 (25.8)	0.542

Table 1 Patients demographic and clinical characteristics (*Continued*)

	All (n = 200)	Levosimendan (n = 53)	Control (n = 147)	p value
Biological parameters				
Hemoglobin level (g/dL)	113 ± 25	114 ± 26	113 ± 24	0.717
International normalized ratio	1.6 ± 0.6	1.5 ± 0.5	1.6 ± 0.6	0.338
Arterial blood pH	7.26 ± 0.1	7.27 ± 0.1	7.26 ± 0.1	0.652
Lactate level (mmol/L)	7.2 ± 5.1	6.4 ± 4.7	7.5 ± 5.3	0.178
Creatinine level (µmol/L)	152 ± 78	150 ± 77	153 ± 79	0.843
Total bilirubin level (µmol/L)	23 ± 17	22 ± 17	24 ± 17	0.457
ASAT (U/L)	763 ± 1819	717 ± 1454	781 ± 1945	0.828
ALAT (U/L)	390 ± 907	295 ± 610	426 ± 998	0.372
Catecholamines during ICU stay				
Norepinephrine max dose (µg/kg/min)	1.49 ± 1.05	1.56 ± 1.07	1.47 ± 1.04	0.586
Norepinephrine duration (days)	10.9 ± 8.7	12.8 ± 7.2	10.2 ± 9.2	0.068
Dobutamine max dose (µg/kg/min)	9.7 ± 4.6	10.4 ± 10.2	9.5 ± 4.3	0.309
Dobutamine duration (days)	9.1 ± 7.9	10.3 ± 10.2	8.6 ± 6.6	0.203

ICU intensive care unit, BMI body mass index, SAPS-II simplified acute physiology score, SOFA sequential organ failure assessment, LVEF left ventricular ejection fraction, TAPSE tricuspid annular plane systolic excursion, MAP mean arterial pressure, HR heart rate, CVP central venous pressure, ScvO₂ central venous oxygen saturation, FiO₂ fractional inspired oxygen, IABP intra-aortic balloon pump, ASAT aspartate aminotransferase, ALAT alanine aminotransferase

Table 2 Balance of covariates before and after matching

Variable (mean)	Unmatched*			Matched		
	Levosimendan (n = 48)	Control (n = 128)	p	Levosimendan (n = 48)	Control (n = 78)	p
Age (years)	53.9	52.6	0.575	54.3	54.7	0.866
Male (%)	62	65	0.692	62	65	0.785
Potential for recovery	2.32	2.12	0.104	2.31	2.35	0.747
SAPS-II	53.5	51.7	0.424	52.7	52.1	0.824
SOFA	11.5	11.8	0.530	11.3	11.5	0.687
LVEF (%)	18	20.2	0.241	18	17	0.690
VA-ECMO duration (days)	10.6	6.5	< 0.001	10.8	10.2	0.478
Serum lactate level (mmol/L)	6.4	7.5	0.178	6.3	6.1	0.816

Myocardial recovery potential: High 1 intermediate 2, Low 3 SAPS-II simplified acute physiology score, SOFA sequential organ failure assessment, LVEF left ventricular ejection fraction. Data are expressed as mean. The p value refers to a comparison between the levosimendan group and the control group. *Compared to the entire cohort (n = 200), the unmatched population had 176 patients since there were 24 patients with missing data on some of the variables used in the analysis